Edit

Incline

http://www.themedicinescompany.com/

Last activity: 24.07.2024

Active - Reference to Novartis

Categories: Care

The Medicines Company is a biopharmaceutical company whose purpose is to halt the deadly progression of atherosclerosis and the cardiovascular risk created by high levels of LDL-C, or bad cholesterol. The team is focused on transformational solutions that address the daily challenges which patients, physicians and payers confront in cardiovascular care. The company is headquartered in Parsippany, New Jersey.

Mentions

Location: United States, New Jersey, Parsippany-Troy Hills

Employees: 51-200

Founded date: 1996

Twitter

Investors 2

Date	Name	Website
-	5AM Ventur...	5amventure...
-	Foresite C...	foresiteca...

Mentions in press and media 16

Date	Title	Description
27.07.2024	The Future of Brain Health: Innovations and Leadership in Alzheimer's and Multiple Sclerosis Treatments	In the ever-evolving landscape of biotechnology, two companies are making waves in the treatment of chronic neurological diseases: Immunic, Inc. and Neurophet. Both are leveraging advanced technologies and seasoned leadership to tackle the ...
24.07.2024	Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec	– Senior Executive and Thought Leader in Brain Health with Nearly Three Decades of Global Pharmaceutical Experience – – Served as Neuroimmunology Franchise Head Responsible for Roche's Blockbuster Launch of Multiple Sclerosis Therapy Ocrevu...
25.11.2019	Top tech startup news for today, Monday, November 25, 2019 – Ebay, Novartis AG, Scribd , StubHub, Frame.io, and Entera	Good morning! Below are some of the top tech startup news for today, Monday, November 25, 2019. Bitcoin sinks to lowest level since May, tumbles $3,000 in a month as China accelerates crackdown. Bitcoin, the world’s most popular cryptocurr...
25.09.2019	The Medicines Co. studies produce further encouraging data on RNAi cholesterol drug	Earlier this month, the company announced positive top-line data from another Phase III study, ORION-11, which was also in ASCVD. The company has said previously that it will begin regulatory filings in the U.S. in the fourth quarter of thi...
21.05.2019	New antibiotics are urgently needed, but economics stand in the way	Achaogen’s journey from promise to penury illustrates the Herculean task the biopharma industry faces: Fulfill a growing need for antibiotics while facing economic realities that make doing so unprofitable. As is apparent from the prolifera...
20.05.2019	Long-term inclisiran data suggest The Medicines Company/Alnylam drug will flourish in pivotal study, disrupt 'bad' cholesterol market	Ahead of the keenly anticipated pivotal late-stage readout for its Alnylam $ALNY-partnered long-acting cholesterol fighter inclisiran, The Medicines Company on Saturday afternoon unveiled long-term Phase II data t...
31.08.2016	Protocols: With Ninlaro sales suffering, Takeda launches huge multiple myeloma study; Medivir splitting, spinning R&D into a separate company	Takeda is rolling out a major new study involving multiple myeloma patients. Researchers are recruiting 5,000 patients to track their real world experience in being treated for the disease. Takeda bagged an FDA approval...
31.05.2016	MaxiVax awarded a grant worth CHF 300,000 to evaluate MaxiVAX cancer vaccine
23.06.2015	Canaan, Vivo Capital, Frazier raising $21.3M for stealth infectious disease startup	Canaan and Frazier Healthcare are your typical life sciences VCs; Vivo Capital, however, focuses on building companies both stateside and in China. Photo: Flickr user Fun Flying Promoted This Patient Experience Checklist Is Your Key To Succ...
10.11.2014	Right after Novartis takes stake in proteomics company, it raises $16.5M	SomaLogic has outlined its proteomics applications in a number of spaces: Though the privately held SomaLogic has been around more than a decade, it’s raised $46.5 million since 2010. Promoted This Patient Experience Checklist Is Your Key T...
05.08.2013	Medicines Buys ProFibrix, Led by Former Zymonite, for $90M	Share Share on Facebook Share on Twitter LinkedIn Email Reprints [Updated: 4:55 pm PT] ProFibrix, the Netherlands-based biotech company with a Seattle drug development office, has agreed to be acquired by The Medicines Company for $240 mill...
10.09.2012	Annovation Biopharma Raises $8M in Series A Funding	Annovation Biopharma, a Wayland, Massachusetts-based biotechnology company focused on creating more effective, safer therapies for anesthesia and critical care, has raised $8m in a Series A funding. The round was led by Atlas Venture, Partn...
-	The Medicines Co. studies produce further encouraging data on RNAi cholesterol drug	The Medicines Company has bolstered previously announced positive data from a Phase III study of an RNA-interference drug that works against PCSK9 with announcements of top-line results from two additional trials. The Parsippany, New Jersey...
-	Canaan, Vivo Capital, Frazier raising $21.3M for stealth infectious disease startup	Three West Coast healthcare venture capital firms – Canaan Partners, Vivo Capital and Frazier Healthcare – are teaming up to launch a stealth new startup called Nexcida Therapeutics. It’s focused on infectious disease therapeutics, CEO Davi...
-	Right after Novartis takes stake in proteomics company, it raises $16.5M	Just a few weeks after Novartis announced it’s taken an ownership stake in Colorado’s SomaLogic, the proteomics company has raised $16.5 million, according to a regulatory filing. Although SomaLogic’s keeping quiet on who’s invested and wha...
-	New antibiotics are urgently needed, but economics stand in the way	On March 10, 2017, shares of antibiotic developer Achaogen traded at $27 on the Nasdaq. Two years later, it has become a penny stock trading at around 9 cents per share after the company filed for bankruptcy under Chapter 11, on April 15, a...

Incline

Investors 2

Mentions in press and media 16

Reviews 0